Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, October 2, 2015

Therapy Focus- The Next Multiple Sclerosis Battleground


Oct. 1, 2015 1:19 PM ET | 

Roche’s (OTCQX:RHHBY) boast on Monday to have in ocrelizumab the first project to show efficacy in a large phase III trial for primary progressive multiple sclerosis is quite a claim, and draws attention to this relatively rare but tricky form of the neurodegenerative disease.


The group might well celebrate: while the relapsing-remitting MS space is crowded, ocrelizumab is one of just a handful of projects in development for the primary progressive form (see table below). However, if Roche has stumbled on a new mechanistic insight this also raises questions that academics and biotechs alike will ask about competing CD20-targeting projects.


Continue learning of this HOPEFUL MS therapy


                              ~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

No comments: